By Stephen Nakrosis
Shares of AnaptysBio were trading higher in the after-hours market following results from the company's rosnilimab trial as a treatment for patients with rheumatoid arthritis.
After the bell, the company's shares were trading 6.2% higher, at $25. The stock closed Tuesday's regular session with a 7.5% gain at $23.52.
The company said in a global 424-patient Phase 2b trial, its investigational rosnilimab demonstrated a best-in-disease profile in patients with moderate to severe rheumatoid arthritis. The company also said rosnilimab demonstrated favorable safety and tolerability, particularly when compared to standard of care biologics or Janus kinase inhibitors.
AnaptysBio said its ongoing Phase 2 study for rosnilimab in ulcerative colitis is on track to report initial data in the fourth quarter.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 03, 2025 18:10 ET (22:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。